| Baxter Announces FDA Approval of Subcutaneous Route of Administration for ... - MarketWatch (press release) |
|
|
MarketWatch (press release) Renal dysfunction, acute renal failure, osmotic nephrosis, and death may occur with immune globulin intravenous (IGIV) products in predisposed patients. Patients predisposed to renal dysfunction include those with any degree of pre-existing renal |